Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 nov. 2025 16h02 HE | Source: NurExone Biologic Inc

NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises

TORONTO and HAIFA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that, further to its...
08 oct. 2025 08h30 HE | Source: NurExone Biologic Inc

NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model

TORONTO and HAIFA, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a biopharmaceutical company developing...
21 janv. 2025 16h20 HE | Source: NurExone Biologic Inc

NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director

NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
27 mars 2024 17h05 HE | Source: NurExone Biologic Inc

Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise

Gross Proceeds close of $4M CAD Generated for NurExone from Warrants Exercise